Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome

• Register: ClinicalTrials.gov
• Last refreshed on: 27 March 2023
• Main ID: NCT02943291
• Date of registration: 21/10/2016
• Prospective Registration: Yes
• Primary sponsor: Norwegian University of Science and Technology
• Public title: Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome HIT-FAT
• Scientific title: Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome
• Date of first enrolment: October 24, 2016
• Target sample size: 15
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02943291
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
• Phase: N/A

Countries of recruitment

Australia, Norway

Contacts

• Name: Jorunn L Helbostad, phd prof
• Affiliation: Norwegian University of Science and Technology

Key inclusion & exclusion criteria

Inclusion Criteria:

- eumenorrheic

- matching PCOC group in IMPROV-IT study (NCT02419482)

- Living nearby St Olavs Hospital, Trondheim, Norway

Exclusion Criteria:

- Signs of hyperandrogenism

- Regular high intensity endurance (two or more times per week of vigorous exercise).

- Concurrent treatments (insulin sensitizers or drugs known to affect gonadotropin or
ovulation, with a wash out period of 1 months prior to inclusion).

- On-going pregnancy

- Hormonal contraception

- Breastfeeding within 24 weeks



Age minimum: 18 Years
Age maximum: 45 Years
Gender: Female

Health Condition(s) or Problem(s) studied

Polycystic Ovary Syndrome

Intervention(s)

Behavioral: 10x1 minute high intensity interval training

Behavioral: 4x4 minutes high intensity interval training

Primary Outcome(s)

production of reactive oxygen species [Time Frame: 16 weeks]

mitochondrial oxidative phosphorylation capacity [Time Frame: 16 weeks]

Secondary Outcome(s)

Adipokine gene expression [Time Frame: 16 weeks]

HDL cholesterol in blood [Time Frame: 16 weeks]

Insulin sensitivity [Time Frame: 16 weeks]

Total protein abundance in adipose tissue [Time Frame: 16 weeks]

"blood markers of cardiometabolic health" [Time Frame: 16 weeks]

blood glucose [Time Frame: 16 weeks]

Adipokine secretion [Time Frame: 16 weeks]

Total cholesterol in blood [Time Frame: 16 weeks]

blood insulin [Time Frame: 16 weeks]

Whole-body peak oxygen uptake [Time Frame: 16 weeks]

endothelial function [Time Frame: 16 weeks]

Glycosylated Hemoglobin (HbA1c) in blood [Time Frame: 16 weeks]

LDL cholesterol in blood [Time Frame: 16 weeks]

lipid droplet size in adipocytes [Time Frame: 16 weeks]

Whole-body fat oxydation rate [Time Frame: 16 weeks]

Intima media thickness [Time Frame: 16 weeks]

blood pressure [Time Frame: 16 weeks]

Body composition [Time Frame: 16 weeks]

Secondary ID(s)

2016/545

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

St. Olavs Hospital

Australian Catholic University

Liverpool John Moores University